{"id":29908,"date":"2025-03-19T11:01:13","date_gmt":"2025-03-19T03:01:13","guid":{"rendered":"https:\/\/flcube.com\/?p=29908"},"modified":"2025-03-19T11:01:15","modified_gmt":"2025-03-19T03:01:15","slug":"celregen-therapeutics-secures-rmb100-million-for-ipsc-regenerative-medicine-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29908","title":{"rendered":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform"},"content":{"rendered":"\n<p>Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company&#8217;s iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.<\/p>\n\n\n\n<p><strong>Company Background and Technology<\/strong><br>Founded in 2022, Celregen Therapeutics boasts iPSC rapid reprogramming technology, an iPSC gene editing platform, and a bioinformatics-guided differentiation technology platform for different germ layers. These platforms cover all upstream and downstream research and development processes of iPSC and its derivative products, positioning Celregen at the forefront of regenerative medicine innovation.<\/p>\n\n\n\n<p><strong>Funding Utilization<\/strong><br>The funds from this financing round will be strategically allocated to several key areas. A significant portion will be dedicated to constructing the iPSC regenerative medicine platform, which will serve as the foundation for developing innovative therapies. Additionally, resources will be directed toward initiating clinical studies for CRG-002 and CRG-101, with the goal of advancing these promising candidates through the development pipeline and ultimately bringing them to market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":29910,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[3575,20],"class_list":["post-29908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-celregen-therapeutics","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company&#039;s iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29908\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform\" \/>\n<meta property=\"og:description\" content=\"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company&#039;s iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29908\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T03:01:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T03:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform\",\"datePublished\":\"2025-03-19T03:01:13+00:00\",\"dateModified\":\"2025-03-19T03:01:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908\"},\"wordCount\":221,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1901-png.avif\",\"keywords\":[\"Celregen Therapeutics\",\"Finance\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29908#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29908\",\"name\":\"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1901-png.avif\",\"datePublished\":\"2025-03-19T03:01:13+00:00\",\"dateModified\":\"2025-03-19T03:01:15+00:00\",\"description\":\"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company's iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29908\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1901-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/1901-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29908#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company's iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29908","og_locale":"en_US","og_type":"article","og_title":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform","og_description":"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company's iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.","og_url":"https:\/\/flcube.com\/?p=29908","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-19T03:01:13+00:00","article_modified_time":"2025-03-19T03:01:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29908#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29908"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform","datePublished":"2025-03-19T03:01:13+00:00","dateModified":"2025-03-19T03:01:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29908"},"wordCount":221,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29908#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","keywords":["Celregen Therapeutics","Finance"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29908#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29908","url":"https:\/\/flcube.com\/?p=29908","name":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29908#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29908#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","datePublished":"2025-03-19T03:01:13+00:00","dateModified":"2025-03-19T03:01:15+00:00","description":"Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital, announced the completion of an angel+ financing round, raising close to RMB100 million (USD13.8 million). The funding was led by Fosun Health Capital and SciNova Investment, with proceeds allocated to constructing the company's iPSC regenerative medicine platform, initiating clinical studies for its differentiated iPSC-derived pancreatic islet cell pipeline CRG-002 and globally leading iPSC-derived corneal endothelial cell therapy CRG-101, as well as researching and developing other early pipelines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29908#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29908"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29908#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","width":1080,"height":608,"caption":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29908#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/1901-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29908"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29908\/revisions"}],"predecessor-version":[{"id":29911,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29908\/revisions\/29911"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29910"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}